About Us
About Next Interactions
At Next Interactions, Inc., we apply the unique expertise of our team and our class-leading platform technologies to your biotech research and development problems.
Services
We offer a suite of services comprising protein-protein interaction (PPI) screens, protein engineering and functional assays. Our clients are in pharma, biotech and academic research.
We use Next-Generation Sequencing (NGS) as the readout, resulting in more complete datasets. Our thoroughly redesigned Y2H system components provide more quantitative and precise measurements of binding partner interactions than conventional Y2H assays. Our platform technology enables us to decipher the full coverage of protein-protein interactions (PPIs). These discoveries have been applied to problems in human health, energy, food security and sustainability.
Why us?
Our team consists of scientists and entrepreneurs with extensive experience in protein interaction technologies, cell signaling and systems biology. We use our platform technology and expertise to decipher more complete and accurate protein-protein interactomes to accelerate your research and product development.
How can we help you?
We have helped our clients with a variety of complex, high impact, difficult projects including the screening for novel tumor suppressor targets, PPIs in hearing disorders, interaction mappings for novel isoforms, plant interaction networks, among other state-of-the-art projects.
Management Team
BERNHARD SUTER
CEO and Co-Founder
I use my expertise in systems biology, yeast genetics and assay development to build perfect solutions for interaction screens. Prior to Next, I held academic positions at the UC Berkeley, the University of Toronto and in Germany
EVELIN SZAKAL
VP of Business Development
I am a business and science professional. Previously I was co-founder and director of corporate development at TheraBiol Inc. I hold a BS in economics, a Ph.D. in medical microbiology from Hungary and completed my postdoc at UCSF studying protein complexes.
Our Team
YONGWON KWON
Senior Scientist
I joined Next Interactions to develop new yeast two-hybrid methods. Prior to joining Next, I discovered novel cancer biomarkers using proteomics and genomics technologies at LBNL and the UCSF Cancer Center. I earned my doctoral degree at Kyoto University, Japan.
ANN HOLTZ-MORRIS
Senior Scientist
I joined Next Interactions to optimize the Next Generation Sequencing based yeast two-hybrid methods. Experienced in both NGS and Y2H technology, I am interested in systems biology and pathway analysis. I also bring Galaxy based bioinformatics analysis skills. I enjoy equally my computer and laboratory work.
RICH YU
Scientific advisor
As a biotech entrepreneur, former venture capital partner and biotech incubator manager, and scientist with experience in protein engineering and systems and synthetic biology, I contribute advise to technical development, company growth, and operations management.
GUSTAVO PESCE
Scientific advisor
I advise on the company’s development of next-gen Protein Protein Interaction assays based on the NGS-Y2H technology.
ANDREW MENDELSOHN
Advisor & Co-founder
I bring 30 years of expertise in molecular, cell and synthetic biology as a biotechnology researcher and serial entrepreneur. I also serve as the Director of Molecular Biology at a Silicon Valley biotechnology incubator and Director of Research at the Regenerative Sciences Institute.